Member Login
Customer Login
(CercleFinance.com) – While lowering its price target from 127 to 120 euros, Invest Securities reiterates its ‘buy’ opinion on bioMérieux, ‘an unfairly discounted stock in the IVD (in vitro diagnostics) industry given its remarkable ability to navigate the Post-Covid era.
The 2024 PER for the next financial year is around 23 times with a yield close to 1%.
Copyright (c) 2024 Cercle Finance. The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.